Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer.
Saved in:
| Title: | Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer. |
|---|---|
| Authors: | Tsimberidou AM; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Guenther K; Immatics Biotechnologies GmbH, Tuebingen, Germany., Andersson BS; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas., Mendrzyk R; Immatics Biotechnologies GmbH, Tuebingen, Germany., Alpert A; Immatics US, Inc., Houston, Texas., Wagner C; Immatics Biotechnologies GmbH, Tuebingen, Germany., Nowak A; Immatics Biotechnologies GmbH, Tuebingen, Germany., Aslan K; Immatics Biotechnologies GmbH, Tuebingen, Germany., Satelli A; Immatics US, Inc., Houston, Texas., Richter F; Immatics Biotechnologies GmbH, Tuebingen, Germany., Kuttruff-Coqui S; Immatics Biotechnologies GmbH, Tuebingen, Germany., Schoor O; Immatics Biotechnologies GmbH, Tuebingen, Germany., Fritsche J; Immatics Biotechnologies GmbH, Tuebingen, Germany., Coughlin Z; Immatics US, Inc., Houston, Texas., Mohamed AS; Immatics US, Inc., Houston, Texas., Sieger K; Immatics US, Inc., Houston, Texas., Norris B; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Ort R; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Beck J; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Vo HH; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Hoffgaard F; Immatics Biotechnologies GmbH, Tuebingen, Germany., Ruh M; Immatics Biotechnologies GmbH, Tuebingen, Germany., Backert L; Immatics Biotechnologies GmbH, Tuebingen, Germany., Wistuba II; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Fuhrmann D; Immatics Biotechnologies GmbH, Tuebingen, Germany., Ibrahim NK; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Morris VK; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Texas., Kee BK; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Texas., Halperin DM; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Texas., Nogueras-Gonzalez GM; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Kebriaei P; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas., Shpall EJ; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas., Vining D; Department of Abdominal Imaging, The University of Texas MD Anderson Cancer Center, Houston, Texas., Hwu P; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Singh H; Immatics N.V., Tuebingen, Germany., Reinhardt C; Immatics N.V., Tuebingen, Germany., Britten CM; Immatics N.V., Tuebingen, Germany., Hilf N; Immatics Biotechnologies GmbH, Tuebingen, Germany., Weinschenk T; Immatics N.V., Tuebingen, Germany., Maurer D; Immatics Biotechnologies GmbH, Tuebingen, Germany., Walter S; Immatics US, Inc., Houston, Texas. |
| Source: | Cancer immunology research [Cancer Immunol Res] 2023 Jul 05; Vol. 11 (7), pp. 925-945. |
| Publication Type: | Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 101614637 Publication Model: Print Cited Medium: Internet ISSN: 2326-6074 (Electronic) Linking ISSN: 23266066 NLM ISO Abbreviation: Cancer Immunol Res Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
